Hagar Ibrahim Labouta

Dr. Hagar Ibrahim Labouta

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta
Marc SchneiderMarc Schneider
Marc Schneider

7 November 2011 in Nanoscale
Verified
Journal Article
Closed access
PDF file
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta
LELabiba K. El-Khordagui
Labiba K. El-Khordagui
TKTobias Kraus
Tobias Kraus
Marc SchneiderMarc Schneider
Marc Schneider
The ability of nanoparticles to penetrate the stratum corneum was the focus of several studies. Yet, there are controversial issues available for particle penetration due to different experimental setups. Meanwhile, there is little known about the mechanism and determinants of their penetration. In this paper the penetration of four model gold nanoparticles of diameter 6 and 15 nm, differing in surface polarity and the nature of the vehicle, through human skin was studied using multiphoton microscopy. This is in an attempt to profoundly investigate the parameters governing particle penetration through human skin. Our results imply that nanoparticles at this size range permeate the stratum corneum in a similar manner to drug molecules, mainly through the intercellular pathways. However, due to their particulate nature, permeation is also dependent on the complex microstructure of the stratum corneum with its tortuous aqueous and lipidic channels, as shown from our experiments performed using skin of different grades of barrier integrity. The vehicle (toluene-versus-water) had a minimal effect on skin penetration of gold nanoparticles. Other considerations in setting up a penetration experiment for nanoparticles were also studied. The results obtained are important for designing a new transdermal carrier and for a basic understanding of skin–nanoparticle interaction.

11 August 2011 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta
DLDavid C. Liu
David C. Liu
LLLynlee L. Lin
Lynlee L. Lin
MBMargaret K. Butler
Margaret K. Butler
JGJeffrey Grice
Jeffrey Grice
TPTarl Prow
Tarl Prow

31 January 2019 in ACS Nano
Verified
Journal Article
Closed access
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta
NANasimeh Asgarian
Nasimeh Asgarian
KRKristina Rinker
Kristina Rinker
DCDavid T. Cramb
David T. Cramb

22 June 2020 in Virulence
Verified
Journal Article
Open access
SGSaeid Ghavami
Saeid Ghavami
MSMadhumita Suresh
Madhumita Suresh
DKDaniel J. Klionsky
Daniel J. Klionsky
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as of May 29th, 2020, WHO). The molecular mechanism of virus infection and spread in the body is not yet disclosed, but studies on other betacoronaviruses show that, upon cell infection, these viruses inhibit macroautophagy/autophagy flux and cause the accumulation of autophagosomes. No drug has yet been approved for the treatment of SARS-CoV-2 infection; however, preclinical investigations suggested repurposing of several FDA-approved drugs for clinical trials. Half of these drugs are modulators of the autophagy pathway. Unexpectedly, instead of acting by directly antagonizing the effects of viruses, these drugs appear to function by suppressing autophagy flux. Based on the established cross-talk between autophagy and apoptosis, we speculate that over-accumulation of autophagosomes activates an apoptotic pathway that results in apoptotic death of the infected cells and disrupts the virus replication cycle. However, administration of the suggested drugs are associated with severe adverse effects due to their off-target accumulation. Nanoparticle targeting of autophagy at the sites of interest could be a powerful tool to efficiently overcome SARS-CoV-2 infection while avoiding the common adverse effects of these drugs.

4 July 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
YAYasmin Abdelkader
Yasmin Abdelkader
LPLuis Perez-Davalos
Luis Perez-Davalos
RLRichard LeDuc
Richard LeDuc
RZRene P. Zahedi
Rene P. Zahedi
HLHagar Ibrahim Labouta
Hagar Ibrahim Labouta